{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:45:11Z","timestamp":1792244711390,"version":"4.4.0"},"reference-count":41,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Richter transformation (RT), a highly aggressive lymphoma arising from a preexisting chronic lymphocytic leukemia, represents a major unmet clinical need. Recent data have shown that an antibody\u2013drug conjugate (ADC) targeting the cell\u2010surface pseudokinase ROR1 is effective in RT patients. In this work, we explored other members of the ROR1 family and focused on RYK as a novel therapeutic target. Transcriptomic analyses revealed that RYK is expressed across multiple lymphoma subtypes, including indolent and aggressive lymphomas, such as RT, while it is absent in peripheral blood mononuclear cells (PBMCs) from healthy donors. To increase the selectivity of the ADC for highly proliferating B\u2010cell malignancies, as a payload we chose an inhibitor of topoisomerase I (TOP1), which is highly expressed in aggressive lymphomas while being undetectable in PBMCs from healthy donors. Based on these premises, we generated SLV\u2010404, an ADC composed of a chimeric antibody directed against the extracellular domain of RYK, a cleavable linker, and the potent TOP1 inhibitor deruxtecan (DXd).\n                    <jats:italic>In vitro<\/jats:italic>\n                    studies in lymphoma cell lines and in cells obtained from RT patient\u2010derived xenografts (RT\u2010PDXs) consistently showed robust induction of apoptosis following SLV\u2010404 treatment, while normal PBMCs were fully resistant. The antitumor activity of SLV\u2010404 was then confirmed\n                    <jats:italic>in vivo<\/jats:italic>\n                    using subcutaneous and intravenous RT\u2010PDX models. Treated animals survived significantly longer with markedly reduced tumor growth and tumor burden. Together, these findings identify RYK as a therapeutic target in aggressive RT and underline the potential of SLV\u2010404 as an ADC\u2010based strategy for the treatment of aggressive lymphomas.\n                  <\/jats:p>","DOI":"10.1002\/hem3.70478","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:24:36Z","timestamp":1790850276000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SLV\u2010404, an anti\u2010RYK antibody\u2013drug conjugate, is effective in Richter transformation patient\u2010derived xenografts"],"prefix":"10.1002","volume":"10","author":[{"given":"Matilde","family":"Micillo","sequence":"first","affiliation":[{"name":"Department of Medical Sciences University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Pirajno","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Edoardo","family":"Vallone","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Navarro\u2010Tableros","sequence":"additional","affiliation":[{"name":"2i3T, Societ\u00e0 Per La Gestione Dell'incubatore Di Imprese e Per Il Trasferimento Tecnologico, University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bolli","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Health Sciences University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Griggio","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Health Sciences University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Lannutti","sequence":"additional","affiliation":[{"name":"Solve Therapeutics, Inc San Diego California United\u00a0States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katti A.","family":"Jessen","sequence":"additional","affiliation":[{"name":"Solve Therapeutics, Inc San Diego California United\u00a0States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3375-6985","authenticated-orcid":false,"given":"Tiziana","family":"Vaisitti","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0632-5036","authenticated-orcid":false,"given":"Silvia","family":"Deaglio","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.829983"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028064"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines14020347"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0708"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2229101"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27021025"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008404"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100001"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02239-1"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3164_427"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-25-0019"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2083"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1823"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8060170"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01543-y"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014760"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.01.030"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02950-8"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2022.04.011"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.615190"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009175"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13137"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.06.018"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-4004"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016211"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/08977194.2018.1472089"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-026-02964-9"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00850-2"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0618"},{"issue":"6","key":"e_1_2_10_31_1","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross PF","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283459"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1803"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01175-0"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0802-5"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13592"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30091-9"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2566871"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3212"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.687926"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70478","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hem3.70478","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:29:16Z","timestamp":1792243756000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hem3.70478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/hem3.70478"],"URL":"https:\/\/doi.org\/10.1002\/hem3.70478","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"value":"2572-9241","type":"print"},{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-05-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70478"}}